FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma
The FDA granted regenerative medicine advanced therapy designation to CB-011, an allogeneic anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma, based on promising clinical data from the CaMMouflage phase 1 trial.
FDA granted RMAT designation to CB-011 for relapsed or refractory multiple myeloma, supporting expedited development and a potential accelerated approval pathway.
Key facts
- CB-011 received RMAT designation for relapsed or refractory multiple myeloma.
- The designation builds on prior fast track and orphan drug designations.
- At the 450 × 10⁶ recommended dose for expansion, anti-BCMA–naive patients achieved a 92% ORR.
- The same cohort showed 75% complete response or better and 91% MRD negativity among evaluable patients.
RMAT designation enables expedited development and potential accelerated approval pathways for CB-011, building on prior fast track and orphan drug designations in relapsed or refractory multiple myeloma. Anti-BCMA–naive patients treated at the 450 × 10⁶ recommended dose for expansion achieved a 92% overall response rate, a 75% complete response rate or better, and 91% minimal residual disease negativity among evaluable patients. CB-011, an allogeneic CAR T product, received RMAT designation as a treatment for multiple myeloma based on strong dose expansion data.
The FDA has granted regenerative medicine advanced therapy designation to CB-011, an allogeneic anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory multiple myeloma (R/R MM). The designation is based on promising early clinical data from the ongoing CaMMouflage phase 1 trial (NCT05722418).
The FDA’s decision was supported by data from the 12-patient cohort of anti-BCMA therapy–naive patients treated at the recommended dose for expansion of 450 × 10⁶ CAR T cells in the dose-escalation phase. As of the September 24, 2025 data cutoff, this cohort demonstrated a 92% overall response rate, a rate of complete response or better of 75%, and minimal residual disease negativity in 91% of evaluable patients.
One patient had a stringent complete response maintained at 15 months post-infusion as of this follow-up. These results represent a clinically meaningful signal in a patient population with significant unmet need, especially in relapsed or refractory multiple myeloma where access, timing and depth of response remain critical issues.
Strong response data support CB-011 in relapsed or refractory multiple myeloma
The CaMMouflage phase 1 study has become an important early test of whether an allogeneic CAR T-cell therapy can generate meaningful efficacy in a disease area where CAR T has already demonstrated clinical value, but where manufacturing timelines and access constraints can limit patient treatment. In this setting, the response rates reported for CB-011 in anti-BCMA–naive patients offer an encouraging signal for the product’s future development.
Among all 48 patients treated, CB-011 has demonstrated a manageable safety profile across all dose levels evaluated. No cases of graft-vs-host disease, immune effector cell–associated enterocolitis, parkinsonism, or cranial nerve palsies were observed. These findings are notable because safety remains one of the most closely watched factors in the advancement of allogeneic cell therapies.
Manageable safety profile seen across dose levels
Among the 35 patients treated with the selected cyclophosphamide and fludarabine lymphodepletion regimen, the most common treatment-emergent adverse events were neutropenia (80%), anemia (60%), thrombocytopenia (49%), infections (49%), dizziness (31%), and cytokine release syndrome (31%). While these adverse events reflect the intensity of treatment in this patient population, the overall safety profile was described as manageable across the evaluated dose levels.
“The FDA’s RMAT designation for CB-011 recognizes both the significant unmet need in multiple myeloma and the encouraging clinical data we have seen so far in the CaMMouflage trial,” said Tina Albertson, MD, PhD, chief medical officer at Caribou Biosciences.
The FDA’s RMAT designation is particularly meaningful because it may help support a faster regulatory path, closer interaction with the agency, and the possibility of accelerated approval if the therapy continues to generate compelling data. For Caribou Biosciences, the designation strengthens the strategic position of CB-011 within the competitive multiple myeloma treatment landscape.
Allogeneic CAR T could help address access limitations
“Only 1 in 10 people with multiple myeloma in the US are able to receive CAR T-cell therapies due to long wait times and manufacturing limitations,” Adriana Rossi, MD, director of the CAR T and stem cell transplant clinical program at the Center of Excellence for Multiple Myeloma at Mount Sinai and an investigator on the CaMMouflage trial, stated in a news release.
That comment highlights one of the main reasons allogeneic CAR T programs like CB-011 are drawing interest. If such therapies can preserve strong efficacy while improving availability and reducing treatment delays, they may help extend CAR T-cell therapy to more patients with relapsed or refractory multiple myeloma who currently cannot access individualized autologous treatment in time.
Caribou Biosciences, the sponsor, anticipates reporting initial dose expansion data and longer follow-up from the dose-escalation cohort in 2026. The company also plans to initiate discussions with the FDA regarding the future clinical development pathway for CB-011. Those next steps will be important in determining whether the RMAT designation can translate into a streamlined path toward later-stage development and possible regulatory approval.
